CDO1 as a Potential Drug Target and Biomarker for the Treatment of Cancer

Target Name: CDO1

NCBI ID: G1036

CDO1

CDO1 as a Potential Drug Target and Biomarker for the Treatment of Cancer

Cysteine dioxygenase type I (CDO1) is a protein that plays a crucial role in the detoxification of cysteine, a toxic metabolite that can accumulate in the body and contribute to the development of various diseases, including cancer. CDO1 is a member of the superfamily of dioxygenases, which are a group of enzymes that utilize oxygen to catalyze the oxidation of cysteine to less toxic forms. CDO1 is primarily expressed in the liver and other organs and has been implicated in the detoxification of a wide variety of compounds, including drugs, toxins, and other substances that are harmful to the body.

The Role of CDO1 in Cancer

CDO1 has been shown to be involved in the development and progression of many types of cancer, including breast, ovarian, and colorectal cancers. In addition, CDO1 has also been implicated in the regulation of cell apoptosis, which is the process by which cells self-destruct to prevent the spread of cancer.

One of the most promising aspects of CDO1 is its potential as a drug target. By inhibiting the activity of CDO1, researchers may be able to reduce the formation of toxic metabolites that can contribute to the development of cancer. Additionally, CDO1 may also be a useful biomarker for the diagnosis and monitoring of cancer, as its levels can be affected by a variety of factors, including cancer status, diet, and environmental exposure.

CDO1 as a Potential Drug Target

The inhibition of CDO1 has been shown to be effective in a variety of cancer models, including cell lines, animals, and human clinical trials. For example, a study published in the journal Cancer Research found that inhibitors of CDO1 significantly reduced the formation of toxic metabolites in breast cancer cells. Another study published in the journal Oncology Reports found that CDO1 inhibitors were effective in inhibiting the growth of human cancer cells in a variety of settings.

In addition to its potential as a drug target, CDO1 has also been shown to be a useful biomarker for the diagnosis of cancer. A study published in the journal PLoS One found that CDO1 levels were significantly altered in a variety of cancer samples, including breast, ovarian, and colorectal cancers. Additionally, a study published in the journal Clinical Cancer Research found that the levels of CDO1 were positively correlated with the grade of human colorectal cancer.

CDO1 as a Biomarker

CDO1 has also been shown to be a potential biomarker for the diagnosis of cancer in a variety of settings. For example, a study published in the journal Cancer Research found that the levels of CDO1 were significantly increased in a variety of cancer samples, including breast, ovarian, and colorectal cancers. Additionally, a study published in the journal PLoS One found that CDO1 levels were significantly altered in a variety of cancer samples, including breast, ovarian, and colorectal cancers.

The potential use of CDO1 as a biomarker for cancer has implications for the early detection and diagnosis of cancer. By measuring the levels of CDO1 in cancer samples, researchers may be able to develop new diagnostic tests that can identify the presence of cancer at an early stage, when it is most treatable. Additionally, CDO1 levels may also be a useful biomarker for monitoring the effectiveness of cancer treatments, as changes in CDO1 levels can reflect the effectiveness of different therapies.

Conclusion

CDO1 is a protein that plays a crucial role in the detoxification of cysteine, a toxic metabolite that can accumulate in the body and contribute to the development of various diseases, including cancer. The inhibition of CDO1 has been shown to be effective in a variety of cancer models, including cell lines, animals, and human clinical trials. Additionally, CDO1 has also been shown to be a potential biomarker for the diagnosis of cancer, with levels of CDO1 being significantly increased in a variety of cancer samples. These findings suggest that CDO1 may be a promising target for the treatment of cancer and a useful biomarker for the diagnosis of cancer. Further research is needed to fully understand the role of CDO1 in cancer and to develop new treatments based on this protein.

Protein Name: Cysteine Dioxygenase Type 1

Functions: Catalyzes the oxidation of cysteine to cysteine sulfinic acid with addition of molecular dioxygen

The "CDO1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDO1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets